Arbutus Biopharma Corporation
ABUS
$3.14
$0.020.64%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 17.55% | -22.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.55% | -22.42% | |||
| Cost of Revenue | -38.28% | -8.22% | |||
| Gross Profit | 44.05% | 6.44% | |||
| SG&A Expenses | 85.85% | -39.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.34% | -18.56% | |||
| Operating Income | 10.32% | 18.25% | |||
| Income Before Tax | 36.44% | 0.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 36.44% | 0.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.44% | 0.40% | |||
| EBIT | 10.32% | 18.25% | |||
| EBITDA | 10.50% | 18.47% | |||
| EPS Basic | 36.63% | 0.95% | |||
| Normalized Basic EPS | 9.79% | 19.97% | |||
| EPS Diluted | 33.56% | 0.95% | |||
| Normalized Diluted EPS | 9.79% | 19.97% | |||
| Average Basic Shares Outstanding | 0.37% | 0.51% | |||
| Average Diluted Shares Outstanding | 0.37% | 0.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
